Recommended relative potency factors for 2,3,4,7,8-pentachlorodibenzofuran: The impact of different dose metrics

Toxicological Sciences

Volumn 91, Issue 1, 2006, Pages 275-285

  Budinsky, Robert A ^a   Paustenbach, Dennis ^b   Fontaine, Donald ^a   Landenberger, Bryce ^a   Starr, Thomas B ^c  

^a DOW CHEMICAL COMPANY   (United States)

^b CARDNO CHEMRISK   (United States)

^c TBS Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,7,8 PENTACHLORODIBENZOFURAN; DIBENZOFURAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY BURDEN; CANCER INCIDENCE; CHI SQUARE TEST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DRUG DISTRIBUTION; LIVER CANCER; LIVER TOXICITY; LONG TERM EXPOSURE; NONHUMAN; PREDICTION; RISK ASSESSMENT; TISSUE DISTRIBUTION;

AREA UNDER CURVE; BENZOFURANS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER NEOPLASMS; MONTE CARLO METHOD; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 33645837822     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfj125     Document Type: Article

References (44)

1. Bailer, A. J., and Portier, C. J. (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 44, 417-431.
2. Brewster, D. W., and Birnbaum, L. S. (1987). Disposition and excretion of 2,3,4,7,8-pentachlorodibenzofuran in the rat. Toxicol. Appl. Pharmacol. 90, 243-252.
3. Brown, R. P, Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., and Beliles, R. P. (1997). Physiological parameters values for PBPK models. Toxicol. Ind. Health 13, 407-484.
4. Budinsky, R., Starr, T. B., Paustenbach, D., Landenberger, B., and Fontaine, D. (2004). A preliminary evaluation of the toxic equivalency factor (TEF) for 2,3,4,7,8-PCDF (4-PCDF) using data from the recent NTP dioxin bioassays. Organohalogen Cmpd. 66, 3433-3438.
5. Carrier, G., Brunet R. C., and Brodeur, J. (1995). Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofurans in mammalians, including humans. II. Kinetics of absorption and disposition of PCDDs. Toxicol. Appl. Pharmacol. 131, 267-276.
6. DeVito, M. J., and Birnbaum, L. S. (1995). The importance of pharmacokinetics in determining the relative potency of 2,3,7,8-tetrachlorodibenzo-pdioxin and 2,3,7,8-tetrachlorodiebenzofuran. Fundam. Appl. Toxicol. 24, 145-148.
7. DeVito, M. J., Diliberto, J. J., Ross, D. G., Menache, M. G., and Birnbaum, L. S. (1997). Dose-response relationships for polyhalogenated dioxins and dibenzofurans following subchronic treatment in mice. Toxicol. Appl. Pharmacol. 147, 267-280.
8. Finley, B. L., Connor, K. T., and Scott, P. K. (2003). The use of toxic equivalency factor distributions in probabilistic risk assessment for dioxins, furans, and PCBs. J. Toxicol. Environ. Health 66, 533-550.
9. Fontaine, D. D., Paustenbach, D., Landenberger, B. D., Budinsky, R. A., and Starr, T. B. (2004). An evaluation of the toxic equivalency factor (TEF) for 2,3,4,7,8-PCDF (4-PCDF) using data from the recent NTP dioxin bioassays. Paper W8.7. Society for Risk Analysis Annual Meeting, 2004.
10. Grassman, J. A., Needham, L. L., Masten, S. A., Patterson, D., Portier, C. J., Lucier, G.W., andWalker, N. J. (2000). Evidence of hepatic sequestration of dioxins in humans? An examination of tissue levels and CYP1A2 expression. Organohalogen Cmpds. 48, 87-90.
11. Harper, N., Connor, K., and Safe, S. (1993). Immunotoxic potencies of polychlorinated biphenyl (PCB), dibenzofuran (PCDF) and dibenzo-p-dioxin (PCDD) congeners in C57BL/6 and DBA/2 mice. Toxicology 80, 217-227.
12. Haws, L. C., Su, S. H., Harris, M., DeVito, M. J., Walker, N. J., Farland,W. H., Finley, B., and Birnbaum, L. S. (2005). Development of a refined database of mammalian relative potency estimates for dioxin-like compounds. Toxicol. Sci. 89, 4-30.
13. Iida, T., Hirakawa, H., Matsueda, T., Nagayama, J., and Nagata, T. (1999). Polychlorinated dibenzo-p-dioxins and related compounds: Correlations of levels in human tissues and in blood. Chemosphere 38, 2767-2774.
14. Kociba, R. J., Keyes, D. G., Beyer, J. E., Carreon, R. M.,Wade, C. E., Dittenber, D. A., Kalnins, R. P., Frauson, L. E., Park, C. N., Barnard, S. D., et al. (1978). Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol. 46, 279-303.
15. Kitamura, K., Nagao, M., Yamada, T., Sunaga, M., Hata, J., and Watanabe, S. (2001). Dioxins in bile in relation to those in the human liver and blood. J. Toxicol. Sci. 26, 327-336.
16. Kreuzer, P. E., Csanady, G. A., Baur, C., Kessler,W., Papke, O., Greim, H., and Filser, J. G. (1997). 2,3,7,8-Tetrachlorodbenzo-p-dioxin (TCDD) and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with special emphasis on its uptake by nutrition. Arch. Toxicol. 71, 383-400.
17. Liang, H. C. L., McKinnon, R. A., and Nebert, D. (1997). Sensitivity of CYP1A1 mRNA inducibility by dioxin is the same in CYP1a2 (+/+) wild-type and Cyp1A2 (-/-) null mutant mice. Biochem. Pharmacol. 54, 1127-1131.
18. Neubert, D., Golor, G., and Neubert, R. (1992). TCDD-toxcity equivalencies for PCDD/PCDF congeners: Prerequisites and limitations. Chemosphere 25, 65-70.
19. NHANES (2005). National Center for Health Statistics. Third National Report on Human Exposure to Environmental Chemicals. U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Environmental Health, NCEH Pub. No. 05-0579.
20. NTP (2003a). Toxicology and carcinogenesis studies of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) in female Harlan Sprague-Dawley rats. NTP TR 525, NIH Publication No 04-4461.
21. NTP (2003b). Toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo- p-dioxin in female Harlan Sprague-Dawley rats. NTP TR 521, NIH Publication No 04-4455.
22. NTP (2003c). Toxicology and carcinogenesis studies of 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126) in female Harlan Sprague-Dawley rats. NTP TR 520, NIH Publication No 04-4454.
23. NTP (2003d). Toxicology and carcinogenesis studies of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) and 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126) in female Harlan Sprague-Dawley rats. NTP TR 526, NIH Publication No 04-4462.
24. Olson, J. R., Bellin, J. S., and Barnes. D. C. (1989). Reexamination of data used for establishing toxicity equivalence factors (TEFS) for chlorinated dibenzo-p-dioxins and dibenzofurans (CDDS and CDFS) Chemosphere 18, 371-381.
25. Patterson, D. G., Todd, G. D., Turner, W. E., Maggio, V., Alexander, L. R., and Needham, L. L. (1994). Levels of non-ortho-substituted (coplanar), monoand di-ortho-substituted polychlorinated biphenyls, dibenzo-p-dioxins, and dibenzofurans in human serum and adipose tissue. Environ. Health Perspect. 103(Suppl. 1), 195-204.
26. Petreas, M., She, J., Winkler, J., Visita, P., McKinney, M., Reynolds, P., Smith, D., Gilliss, D., Hurley, S., Jeffrey, S., et al. (2000). Body burdens of organohalogens in California populations. Organohalogen Cmpds. 48, 17-20.
27. Pluss, N., Poiger, H., Hohbach, C., Suter, M., and Schlatter, C. (1988). Subchronic toxicity of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) in rats. Chemosphere 17, 1099-1110.
28. Safe, S. H. (1998). Development validation and problems with the toxic equivalency factor approach for risk assessment of dioxins and related compounds. J. Animal Sci. 76, 134-141.
29. Slezak, B. P., Diliberto, J. J., and Birnbaum, L. S. (1999). 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated oxidative stress in CYP1A2 knockout (CYP1A2-/-) mice. Biochem. Biophys. Res. Commun. 264, 376-379.
30. Smialowicz, R. J., Burgin, D. E.,Williams,W. C., Diliberto, J. J., Setzer, R.W., and Birnbaum, L. S. (2004). CYP1A2 is not required for 2,3,7,8-tetrachloordibenzo-p-dioxin-induced immunosuppression Toxicology 197, 15-22.
31. Smith, A. G., Clothier, B., Carthew, P., Childs, N. I., Sinclar, P. R., Nebert, D.W., and Dalton, T. P. (2001). Protection of the Cyp 1a2 (-/-) null mouse against urophorphyia and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 173, 89-98.
32. Toyoshiba, H., Walker, N. J., Bailer, J. A., and Portier, C. J. (2004). Evaluation of toxic equivalency factors for induction of cytochrome P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds. Toxicol. Appl. Pharmacol. 194, 156-168.
33. USEPA. (1988). A cancer risk-specific dose estimate for 2,3,7,8-TCDD. Appendices A Through F. EPA/600/6-88/007-AB.
34. USEPA. (2001). Benchmark Dose Software. Version 1.3.2 downloaded from http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=20167, March 2004.
35. USEPA. (2003a). Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds. Washington, DC, National Academy Sciences (NAS) Review Draft, December 2003.
36. USEPA. (2003b). Framework for Application of the Toxicity Equivalence Methodology for Polychlorinated Dioxins, Furans, and Biphenyls in Ecological Risk Assessment. EPA/630/P-03/002A, June 2003.
37. USEPA. (2004). An Examination of EPA Risk Assessment Principles and Practices. EPA/100/B-04/001, March 2004.
38. van Birgelen, A. P. J. M., DeVito, M. J., Orzech, D., Walker, N., Birnbaum, L. S., Bucher, J., and Lucier, G. (1997). Design of 2-year bioassays with dioxin-like compounds in female Sprague-Dawley rats. Organohalogen Cmpds. 34, 154-159.
39. Van den Berg, M., Bouwman, C., and Seinen, W. (1989). Hepatic retention of PCDDs and PCDFs in C57BL/6 and DBA/2 mice. Chemosphere 19, 795-782.
40. Van den Berg, M., Birnbaum, L., Bosveld, A. T., Brunstrom, B., Cook, P., Feeley, M., Giesy, J. P., Hanberg, A., Hasegawa, R., Kennedy, S. W., et al. (1998). Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. Environ. Health Perspect. 106, 775-792.
41. Waern, F., Flodstrom, S., Busk, L., Kornevi, T., Nordgren, I., and Ahlborg, U. G. (1991). Relative liver tumour promoting activity and toxicity of some polychlorinated dibenzo-p-dioxin- and dibenzofuran-congeners in female Sprague-Dawley rats. Pharmacol. Toxicol. 69, 450-458.
42. Walker, N. J., Crockett, P., Nyska, A., Brix, A., Kokinen, M. P., Sells, D. M., Hailey, J. R., Easterling, M., Haseman, J. K., Yin, M., et al. (2005). Dose-additive carcinogenicity of a defined mixture of dioxin-like compounds. Environ. Health Perspect. 113, 43-48.
43. Wittsiepe, J., Furst, P., Schrey, P., Lemm, F.,Kraft, M., Eberwein, G.,Winneke,G., and Wilhelm, M. (2004). PCDD/F and dioxin-like PCB in human blood and milk from German mothers. Organohalogen Cmpds. 66, 2865-2872.
44. Wittsiepe, J., Schrey, P., Ewers, U., Selenka, F., and Wilhelm, M. (2000). Decrease of PCDD/F levels in human blood from Germany over the past ten years (1989-1998). Chemosphere 40, 103-110.